U.S., Jan. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07329322) titled 'Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib or Sacituzumab Tirumotecan for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer' on Dec. 11, 2025.
Brief Summary: The aim of the study to evaluate the safety and efficacy of Sacituzumab Tirumotecan in combination with osimertinib or as monotherapy for neoadjuvant treatment in patients with resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer.
Study Start Date: Feb. 01
Study Type: INTERVENTIONAL
Condition:
Non-Small Cell Lung Cancer
Intervention:
D...